A method for treating anxiety disorders, affective disorders, intracranial injury, spinal cord injury, neurodegenerative diseases, sclerosis, migraine, fibromyalgia and cerebrovascular disease, using melatonin derivatives is disclosed. A specific melatonin derivative for use in the disclosed process is 13-methyl-6-chloromelatonin (otherwise referred to as (R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide).

 
Web www.patentalert.com

< Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression

< Therapeutic combination

> N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

> Device and method for positioning of a therapeutic device

~ 00293